Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2017
SIETES contiene 92082 citas

 
 
 1 a 20 de 123 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Chan WY, Clark AB, Wilson AM, Loke YK, on behalf of the TIPAC investigators. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101544]
3.Enlace a cita original
Anónimo. Sacubitril/valsartan for chronic heart failure. Australian Prescriber 2016;39:221. [Ref.ID 101024]
5. Cita con resumen
Anónimo. Sacubitril + valsartan et insuffisance cardiaque chronique. Prescrire 2016;36:645-50. [Ref.ID 100816]
6.Tiene citas relacionadas Cita con resumen
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodríguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright Jr JT, Pajewski NM, for the SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged =75 years: a randomized clinical trial. JAMA 2016;315:2673-82. [Ref.ID 100474]
7. Cita con resumen
8.Tiene citas relacionadas
Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the finish. N Engl J Med 2015;373:2174-5. [Ref.ID 99776]
9.Tiene citas relacionadas
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]
10.Tiene citas relacionadas Cita con resumen
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2013-6. [Ref.ID 99661]
11. Cita con resumen
Kelley KJ. Oral hyperkalemia drug approved. Journal Watch 2015:23 de octubre. [Ref.ID 99572]
12.Tiene citas relacionadas Cita con resumen
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68. [Ref.ID 99524]
13.Tiene citas relacionadas Cita con resumen
Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61. [Ref.ID 99346]
14.Tiene citas relacionadas Cita con resumen
Winkelmayer WC. Treatment of hyperkalemia: from "hyper K" striketout to home run?. JAMA 2015;314:129-30. [Ref.ID 99345]
15.Tiene citas relacionadas
Greenland P, Lauer MS. Cholesterol lowering in 2015: still answering questions about how in whom. JAMA 2015;314:127-8. [Ref.ID 99344]
16. Cita con resumen
Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheller DC, Stripooli GFM. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047-56. [Ref.ID 99157]
19. Cita con resumen
Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015;151:941-4. [Ref.ID 98866]
20. Cita con resumen
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-143. [Ref.ID 98851]
Seleccionar todas
 
 1 a 20 de 123 siguiente >>